Novel Type 2 Diabetes Medication Access and Effect of Patient Cost Sharing

Journal of Managed Care & Specialty Pharmacy
Henry J HenkBrahim Bookhart

Abstract

Although drug formulary restrictions may reduce use of prescription medication and pharmacy costs, the effect of patient cost sharing on medication adherence and health care utilization and cost is unclear. To evaluate the relationship between patient cost sharing for novel type 2 diabetes mellitus (T2DM) medications and medication adherence, persistence, and health care utilization and cost. This retrospective study used medical and pharmacy claims linked to pharmacy benefit plan design data. Patients with T2DM were identified via ICD-9-CM codes (medical claims), outpatient prescription fills (pharmacy claims), and pharmacy benefit design information. Patients with T2DM treated with novel T2DM medications (DPP4 or GLP-1) were enrolled in plans with fixed or coinsurance medication copayment structures and followed for 12-48 months. Endpoints included medication persistence and adherence and total all-cause health care cost. Multivariable regression analysis estimated the effect of benefit design parameters, adjusting for baseline patient characteristics. The integrated database included 36,475 patients with T2DM. The majority (83.1%) had fixed copayment plans, and 3-tier plans were common (93.1%). Higher third-tier copayment wa...Continue Reading

References

Sep 15, 1996·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·S D Horn
Dec 24, 1997·Diabetes Care·T P GilmerW A Rush
Feb 15, 2001·JAMA : the Journal of the American Medical Association·E H WagnerL C Grothaus
Jul 27, 2001·Journal of Health Economics·W G Manning, J Mullahy
May 24, 2005·Medical Care·Michael C SokolRobert S Epstein
Sep 27, 2006·Archives of Internal Medicine·P Michael HoDavid J Magid
Jul 5, 2007·JAMA : the Journal of the American Medical Association·Dana P GoldmanYuhui Zheng
May 13, 2008·Journal of Occupational and Environmental Medicine·Alberto M ColombiJulie Priest
Jun 19, 2008·Medical Care Research and Review : MCRR·Michael Chernew, Teresa B Gibson
Jun 22, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Feng ZengMichael B Nichol
Jan 7, 2011·Health Affairs·M Christopher RoebuckTroyen A Brennan
Mar 14, 2012·Annals of Family Medicine·Elizabeth A BaylissJohn F Steiner
Mar 8, 2013·Diabetes Care·UNKNOWN American Diabetes Association
Aug 11, 2016·Journal of Diabetes and Its Complications·Kristi ReynoldsSwapnil N Rajpathak

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.